<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168037">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01737099</url>
  </required_header>
  <id_info>
    <org_study_id>2012-1048</org_study_id>
    <nct_id>NCT01737099</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia</brief_title>
  <acronym>DHA-O</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DSM Nutritional Products, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of DHA-O to lower
      elevated triglyceride levels in healthy adults with hypertriglyceridemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in TG levels</measure>
    <time_frame>week 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lipid panel measures</measure>
    <time_frame>week 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>DHA-O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA-O</intervention_name>
    <arm_group_label>DHA-O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <arm_group_label>Fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18-79

          -  fasting TG levels, 150-499 mg/dL

          -  baseline DHA intake &lt;200mg/d

          -  active and in good health

        Exclusion Criteria:

          -  recent diagnosis of CHD or history of revascularization within 6mos of study

          -  use of lipid altering medications (other than stable statins)

          -  use of anticoagulants

          -  use of omega-3 products within 4 weeks of screening

          -  serum AST/ALT &gt;1.5x ULN and/or creatinine &gt;1.5 mg/dL at screening

          -  lipid altering foods or supplements

          -  women who are pregnant or of childbearing potential not using adequate birth control

          -  current use or history of  drug or alcohol abuse

          -  inability to swallow capsules
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Maki, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofortis Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biofortis Clinical Research</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>omega-3</keyword>
  <keyword>DHA</keyword>
  <keyword>triglycerides</keyword>
  <keyword>lipids</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
